Source:http://linkedlifedata.com/resource/pubmed/id/12448658
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
2002-11-22
|
| pubmed:abstractText |
This study addressed the efficacy and toxicity of the novel compound Bryostatin-1 (NSC 339555), a novel agent with antineoplastic, hematopoietic and immunomodulatory activity in a variety of in vitro and in vivo systems.
|
| pubmed:language |
eng
|
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:author |
pubmed-author:BerlangerKK,
pubmed-author:Burdette-RadouxSS,
pubmed-author:DavisM LML,
pubmed-author:LohmannR CRC,
pubmed-author:National Cancer Institute of Canada Clinical Trials Group,
pubmed-author:RusthovenJ RJR,
pubmed-author:SeymourLL,
pubmed-author:TozerR GRG,
pubmed-author:WainmanNN,
pubmed-author:ZehEE
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
407-12
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:articleTitle |
A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group study.
|
| pubmed:affiliation |
Cancer Care Ontario-Hamilton, Regional Cancer Centre, Canada.
|